Community-acquired pneumonia in the post 13-valent pneumococcal conjugate vaccine era. Issue 6 (December 2016)

• Record Type: Journal Article
• Authors: Shaughnessy, Erin E.; Stalets, Erika L.; Shah, Samir S.
• Is Part Of: Current opinion in pediatrics. Volume 28:Issue 6(2016:Dec.)
• Page Start: 786
• Page End: 793
• Publication Date: 2016-12
• Subjects: community-acquired pneumonia -- diagnostic evaluation -- pneumococcal conjugate vaccine -- pneumonia -- treatment; Pediatrics -- Periodicals; Pediatrics -- Periodicals -- Bibliography -- Periodicals; 618.92
• DOI: 10.1097/MOP.0000000000000428
• Languages: English
• ISSNs: 1040-8703

Abstract

Abstract : Purpose of review: This review covers the outpatient management of pediatric community-acquired pneumonia (CAP), discussing the changing microbiology of CAP since the introduction of the 13-valent pneumococcal conjugate vaccine in 2010, and providing an overview of national guideline recommendations for diagnostic evaluation and treatment. Recent findings: Rates of invasive pneumococcal disease and pneumococcal antibiotic resistance have plummeted since widespread 13-valent pneumococcal conjugate vaccine immunization. Viruses remain the most common cause of CAP in young children; children over age 5 years have increased rates of Mycoplasma pneumoniae . A recent national guideline offers recommendations for office-based diagnostic evaluation and treatment of pediatric CAP. Summary: This review offers a discussion of the above findings with practical recommendations for the office-based practitioner in the evaluation and treatment of an infant (>3 months) or child with suspected CAP.